Search





Search





Markets
/
Stocks
/
vnrx
/

VolitionRX Ltd

VNRX

Add to Watchlist

0.847USD

-0.033-3.74%

Close 07-28 16:00（ET）Quotes delayed by 15 min

335.90KMarket Cap

LossP/E TTM

VolitionRX Ltd

0.847

-0.033-3.74%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-3.74%

5 Days

-23.68%

1 Month

-33.82%

6 Months

-83.71%

Year to Date

-83.43%

1 Year

+15.99%

Key Figures

0.927Open

0.974High

397.74KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

100.30%Turnover Ratio

0.880Prev. Close

0.847Low

236.16KTurnover

LossP/E Static

-0.01P/B

0.00%Div Yield TTM

-281.72%ROA

18.80052wk High

1.47Volume Ratio

-26.97MNet Profit

396.53KShares

-4.2173EPS TTM

1.06Beta

-5396.85%ROE

1.90652wk Low

14.44%Amplitude

100.00%Gross Margin

335.90KMarket Cap

-7.11Reward/Risk

5.35%Risk Rate

TradingKey Stock Score of VolitionRX Ltd

Currency: USD Updated: 2026-07-28

Key Insights

VolitionRX Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.97.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

VolitionRX Ltd's Score

Industry at a Glance

Industry Ranking

115 / 385

Overall Ranking

208 / 4278

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

VolitionRX Ltd Highlights

StrengthsRisks

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 122.80% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.73M.

Overvalued

The company’s latest PE is -0.20, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.13M shares, decreasing 15.69% quarter-over-quarter.